FibroGen Announces Completion of Patient Enrollment in MATTERHORN, a Phase III Clinical Study of Roxadustat for the Treatment of Anemia in Patients with Lower Risk Transfusion-Dependent Myelodysplastic Syndromes (MDS)

By
Danielle Corrigan
-
0
122
FibroGen, Inc. announced completion of patient enrollment for MATTERHORN, a Phase III clinical study of roxadustat for treatment of anemia in patients with lower risk transfusion-dependent MDS.
[FibroGen, Inc.]
Press Release